AUPH - Aurinia spikes on Q2 earnings beat guidance raise
2023-08-03 06:40:52 ET
More on Aurinia Pharma
- Aurinia: Strategic Alternatives Could Go Either Way For Stakeholders
- Aurinia Pharmaceuticals: Still In The Game With Lupkynis Sales
- Aurinia: Despite Milder Shareholder Vote, A Bid To Sell Is Still Not Over
- Aurinia Pharma could see high $20s to low $30s a share in takeover - analyst
- Seeking Alpha’s Quant Rating on Aurinia Pharma
For further details see:
Aurinia spikes on Q2 earnings beat, guidance raise